

Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

February 4, 2022 | Issue 207

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🧹

Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized COVID-19 news for the week in this special supplement.

0



CMS <u>proposed</u> an average <u>7.98% increase</u> in revenue for 2023 Medicare Advantage plans; CMS also seeks comment on a "health equity index" for Star Ratings.

ASPE <u>reported on disparities in utilization</u> of audio-video vs. audio-only telehealth services.

FDA proposed national standards for wholesale drug distributor licensure.

FDA released guidance on review of drug-device combination products.

HHS announced <u>\$19.2M to expand community-based primary care</u> residency programs.

Justice Department reported <u>healthcare companies accounted for \$5B</u> of \$5.6B in FY2021 False Claims Act settlements.

0



Healthcare law and policy news

President Biden relaunched the "Cancer Moonshot" to <u>cut the cancer</u> death rate in half over 25 years.

KPMG, EBG, and FPP reported 2,918 healthcare and life sciences announced/closed deals in 2021, up from 1,936 in 2020... Beaumont and Spectrum completed their merger... PointClickCare Technologies will acquire Audacious Inquiry... Amedisys plans to acquire Evolution Health... Humana plans to invest \$1B in Medicare Advantage and may divest Kindred at Home's hospice business.

Native American tribes reached <u>a \$590M opioid settlement with</u> <u>Johnson & Johnson</u> and drug distributors... Cardinal Health will <u>pay</u> <u>\$13M to settle kickback</u> allegations... GlaxoSmithKline will <u>receive</u> <u>\$1.25B and royalties from Gilead</u> through an HIV product patent dispute settlement.

Pfizer is the 13th drug manufacturer to <u>restrict 340B discounts to</u> <u>contract pharmacies</u>... Magellan Health will partner with Zipline on <u>drone delivery of some members' medications</u> this year.

JAMA studies found disparities in <u>30-day hospital readmission rates for</u> <u>dual-eligible patients persist even after accounting</u> for state and community-level social factors; just <u>9% of primary care and 4.5% of</u> <u>specialist provider compensation</u> is based on quality and costs; and adolescents/young adults <u>lost 1.2M years of life from unintentional drug</u> <u>overdoses</u> from 2015-2019.

CDC data show more than <u>100,000 Americans died from diabetes in</u> <u>2021</u>, up 15% from pre-pandemic... A *Modern Healthcare* analysis found just 4.3% of hospitals received Hospital-Acquired Condition <u>Reduction penalties</u> in all five years of the program.

Rx Savings Solutions reported roughly 150 drug manufacturers <u>raised</u> 2022 list prices of 866 medicines 6.6%, on average, up from 4.5% last

year... Urban Institute estimated <u>15M individuals could lose Medicaid</u> <u>coverage</u> during redetermination processes after the public health emergency ends.

Healthcare data breaches <u>impacted a record 45 million individuals</u> in 2021.

0



Questions or comments, please send to <u>us-hcinsight@kpmg.com</u>.

Succeeding in the new reality Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Policy Insight



COVID-19 by the Numbers

Roughly 76 million COVID-19 cases have been documented in the US, with a death toll over 895,000... The country is now <u>averaging roughly 400,000 cases/day</u> over the past week, down from approximately 750,000/day just two weeks ago; however, COVID-related deaths continue trending upwards, averaging roughly 2,400/day... Long-term care facility <u>COVID-related deaths surpassed 200,000</u>, accounting for 23% of all deaths in the country... World Health Organization said <u>90 million COVID-19 cases have been</u> <u>reported worldwide since the Omicron variant</u> was first discovered 10 weeks ago, more cases than in all of 2020.

More than <u>10.1 billion COVID-19 vaccine doses have been administered across 184 countries</u>... Over 540 million COVID-19 <u>vaccine doses have been administered</u> in the US (roughly 350,000/day over the past week)... Over 250 million Americans (<u>more than 80% of Americans 5 and older</u>) have received at least one COVID-19 vaccine dose; roughly 212 million Americans are fully vaccinated (roughly 68% of Americans 5 and older); nearly 89 million Americans have received a booster or additional dose (just 42% of those full vaccinated)... CDC data show that <u>only 22% of children ages 5 to 11</u> are fully vaccinated; 31% have received at least one dose.

Executive and Administrative Action

CMS is <u>developing an initiative</u> to cover <u>eight free over-the-counter COVID-19 tests per month</u> for Medicare beneficiaries beginning in the early spring.

Republican Governors of <u>Virginia and West Virginia urged</u> CMS to grant a limited waiver from the healthcare worker COVID-19 vaccine requirement for rural and state-run facilities in order to ensure appropriate staffing to address the pandemic.

The US Army will <u>immediately begin discharging service members</u> who have refused to get the COVID-19 vaccine.

HHS issued <u>new guidance</u> to healthcare providers on <u>civil rights protections for people with disabilities</u> during the public health emergency.

Healthcare Law, Business, and Policy News

A bipartisan, bicameral group of 45 Congressional members asked Congressional leaders to <u>extend</u> <u>pandemic-related telehealth waivers</u> as part of this month's must-pass omnibus legislation.

World Health Organization highlighted the <u>accumulation of tens of thousands of tons of medical waste</u> <u>as a result of the pandemic</u> and <u>recommended strategies</u> for integrating more environmentally sustainable waste practices into future pandemic preparedness efforts.

A CDC study of Los Angeles County public health data found that <u>unvaccinated individuals were 23 times</u> <u>more likely than individuals fully vaccinated</u> with a booster dose to be hospitalized during the Omicron wave.

Recently posted <u>pre-print studies suggest that immunity from Omicron</u> infection <u>does not appear</u> <u>sufficient to prevent</u> infection from <u>other future variants</u>.

Despite an <u>earlier Data for Progress survey</u> showing 64% of likely voters strongly or somewhat support the federal government distributing free N95 masks, <u>only 5% of Americans have picked up free N95</u> <u>masks</u> being distributed.

Surveillance, Testing, and Treatment

FDA granted full approval to Moderna's COVID-19 vaccine, Spikevax.

Novavax is seeking FDA emergency use authorization for its COVID-19 vaccine.

Early data suggest COVID-19 <u>vaccines appear effective against severe disease from an Omicron</u> <u>sublineage</u>, BA.2, which is becoming more common in parts of the world.

Pfizer and BioNTech are <u>seeking emergency use authorization for two doses of their COVID-19 vaccine in</u> <u>children under age 5</u>, FDA's advisory panel will meet on February 15th to consider data and make a recommendation. The CDC is expected to follow soon after, setting the vaccine up to potentially be available for the age group by the end of February... Some vaccine experts are <u>concerned that clinical</u> <u>trial data is not yet available on whether the vaccine is effective for the entire age group</u> and whether a third dose increases immune response.

Pharmacy groups are <u>urging the federal government to require insurers to pay pharmacies</u> more for <u>dispensing Pfizer and Merck's COVID-19 antiviral</u> pills... NPR reported that the federal government is spending roughly \$530M for each five-day course of Pfizer's COVID-19 antiviral, <u>but could get a lower</u> <u>price as a result of most favored nation pricing</u> if other countries get a better deal.

A <u>preliminary ICER analysis concluded</u> that COVID-19 antiviral pills from Merck-Ridgeback Biotherapeutics and Pfizer and the monoclonal antibody treatment from GlaxoSmithKline-Vir Biotechnology appear to be cost-effective.

NIAID released a <u>Pandemic Preparedness Plan</u> targeting <u>prototype pathogens</u> (viruses from families with the potential to cause significant disease) and priority pathogens (those already known to cause significant human harm) in order to more quickly combat future pandemic.